Table_2_Targeting the lncRNA DUXAP8/miR-29a/PIK3CA Network Restores Doxorubicin Chemosensitivity via PI3K-AKT-mTOR Signaling and Synergizes With Inotuzumab Ozogamicin in Chemotherapy-Resistant B-Cell Acute Lymphoblastic Leukemia.docx
This study aimed to determine the expression profiles of long non-coding RNA (lncRNA), microRNA (miRNA), and mRNA in chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL).
MethodsLncRNA, miRNA, and mRNA profiles were assessed by RNA-seq in diagnostic bone marrow samples from 6 chemotherapy-resistant and 6 chemotherapy-sensitive B-ALL patients. The lncRNA DUXAP8/miR-29a/PIK3CA signaling network was identified as the most dysregulated in chemoresistant patient samples, and its effect on cellular phenotypes, PI3K-AKT-mTOR signaling, and chemosensitivity of doxorubicin (Dox)-resistant Nalm-6 (N6/ADR), and Dox-resistant 697 (697/ADR) cells were assessed. Furthermore, its synergy with inotuzumab ozogamicin treatment was investigated.
Results1,338 lncRNAs, 75 miRNAs, and 1620 mRNAs were found to be dysregulated in chemotherapy-resistant B-ALL in comparison to chemotherapy-sensitive B-ALL patient samples. Through bioinformatics analyses and RT-qPCR validation, the lncRNA DUXAP8/miR-29a/PIK3CA network and PI3K-AKT-mTOR signaling were identified as significantly associated with B-ALL chemotherapy resistance. In N6/ADR and 697/ADR cells, LncRNA DUXAP8 overexpression and PIK3CA overexpression induced proliferation and inhibited apoptosis, and their respective knockdowns inhibited proliferation, facilitated apoptosis, and restored Dox chemosensitivity. MiR-29a was shown to affect the lncRNA DUXAP8/PIK3CA network, and luciferase reporter gene assay showed direct binding between lncRNA DUXAP8 and miR-29a, as well as between miR-29a and PIK3CA. Targeting lncRNA DUXAP8/miR-29a/PIK3CA network synergized with inotuzumab ozogamicin’s effect on N6/ADR and 697/ADR cells.
ConclusionTargeting the lncRNA DUXAP8/miR-29a/PIK3CA network not only induced an apoptotic effect on Dox-resistant B-ALL and restored Dox chemosensitivity via PI3K-AKT-mTOR signaling but also showed synergism with inotuzumab ozogamicin treatment.
History
References
- https://doi.org//10.1002/ajh.26156
- https://doi.org//10.1007/s11684-020-0759-8
- https://doi.org//10.1177/2040620716652289
- https://doi.org//10.1007/s11899-017-0380-3
- https://doi.org//10.1080/14656566.2016.1250884
- https://doi.org//10.1007/s11899-020-00591-4
- https://doi.org//10.3390/ijms22116166
- https://doi.org//10.3390/ncrna7020036
- https://doi.org//10.1016/j.lfs.2021.119152
- https://doi.org//10.1016/j.omtn.2020.07.005
- https://doi.org//10.3389/fcvm.2021.632393
- https://doi.org//10.3389/fonc.2020.577890
- https://doi.org//10.3390/cancers13081976
- https://doi.org//10.3389/fonc.2019.00899
- https://doi.org//10.1186/s13045-018-0692-3
- https://doi.org//10.1186/s40364-021-00307-7
- https://doi.org//10.14348/molcells.2020.0065
- https://doi.org//10.1038/s41408-019-0258-9
- https://doi.org//10.1093/annonc/mdw025
- https://doi.org//10.1002/ijc.2910500223
- https://doi.org//10.1182/blood.2019002655
- https://doi.org//10.1038/leu.2011.206
- https://doi.org//10.3390/ijms20020412
- https://doi.org//10.3892/or.2021.8091
- https://doi.org//10.1038/leu.2013.226
- https://doi.org//10.3389/fgene.2021.656042
- https://doi.org//10.3892/ol.2018.9832
- https://doi.org//10.1111/pin.12993
- https://doi.org//10.1042/BSR20193461
- https://doi.org//10.1016/j.brainres.2020.146947
- https://doi.org//10.4274/tjh.galenos.2021.2020.0769
- https://doi.org//10.1016/j.omto.2020.10.010
- https://doi.org//10.26355/eurrev_202003_20682
- https://doi.org//10.1097/MPA.0000000000001751
- https://doi.org//10.1158/1541-7786.MCR-19-0594
- https://doi.org//10.1182/blood-2011-10-385716
- https://doi.org//10.1182/blood.2020005627
- https://doi.org//10.1007/s11033-011-1026-5
- https://doi.org//10.1016/j.omto.2020.01.004
- https://doi.org//10.1590/S0100-879X2007001100003
- https://doi.org//10.1002/jcp.29429
- https://doi.org//10.1016/j.cellsig.2013.09.021
- https://doi.org//10.2147/BLCTT.S223894
- https://doi.org//10.1038/s41408-020-00345-8
- https://doi.org//10.1016/j.leukres.2019.106283
- https://doi.org//10.1002/cncr.32116
- https://doi.org//10.1007/s12185-019-02749-0